Contributions
Abstract: PB2243
Type: Publication Only
Background
Bortezomib, Lenalidomide and Dexamethasone is one of the best option for frontline treatment, approved in USA but not available in Italy.
However, it can show interesting results also in relapsed and refractory patients, thanks to the synergistic effect of these agents.
Aims
In this retrospective observational study, it has been evaluated the safety and efficacy of the combination of bortezomib plus lenalidomide plus dexamethasone (VRD) in patients with relapsed and refractory Multiple Myeloma (rrMM).
Methods
29 patients (19 M, 10 F), with rrMM, median age 64 years (range 38-79), were treated with the VRD regimen (Bortezomib 1.3 mg/sqm days 1,4,8,11; dexamethasone 20 mg days 1, 2, 4, 5, 8, 9, 11, 12 and oral lenalidomide 25 mg daily on days 1-21), with a median of 6 cycles (range 1-21).
Patients had previously received 3 median (range 1-6) lines of therapy. 83% (24/29) of them had undergone to autologous SCT.
Results
According to IMWG, ORR was 79.3% (23/29: 6 CR, 5 VGPR, 7 PR, 5 SD). Median time to response was 3 months (range 1-6), median OS from diagnosis was 56 months (range 12-221).
Bortezomib-lenalidomide-dexamethasone was well tolerated, with grade 1-2 anemia in 5 patients, successfully managed with ESAs, and, thanks to the way of administration, also compliance is good. Peripheral neuropathy was seen in 48% (14/29) patients.
Conclusion
Bortezomib-lenalidomide-dexamethasone triplet, thanks to a notable proved synergistic mechanism of action between bortezomib and lenalidomide, had shown significant efficacy in severe setting of heavily pretreated patients, relapsed and refractory to bortezomib and lenalidomide.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Autologous bone marrow transplant, bortezomib, immunomodulation, Multiple Myeloma
Abstract: PB2243
Type: Publication Only
Background
Bortezomib, Lenalidomide and Dexamethasone is one of the best option for frontline treatment, approved in USA but not available in Italy.
However, it can show interesting results also in relapsed and refractory patients, thanks to the synergistic effect of these agents.
Aims
In this retrospective observational study, it has been evaluated the safety and efficacy of the combination of bortezomib plus lenalidomide plus dexamethasone (VRD) in patients with relapsed and refractory Multiple Myeloma (rrMM).
Methods
29 patients (19 M, 10 F), with rrMM, median age 64 years (range 38-79), were treated with the VRD regimen (Bortezomib 1.3 mg/sqm days 1,4,8,11; dexamethasone 20 mg days 1, 2, 4, 5, 8, 9, 11, 12 and oral lenalidomide 25 mg daily on days 1-21), with a median of 6 cycles (range 1-21).
Patients had previously received 3 median (range 1-6) lines of therapy. 83% (24/29) of them had undergone to autologous SCT.
Results
According to IMWG, ORR was 79.3% (23/29: 6 CR, 5 VGPR, 7 PR, 5 SD). Median time to response was 3 months (range 1-6), median OS from diagnosis was 56 months (range 12-221).
Bortezomib-lenalidomide-dexamethasone was well tolerated, with grade 1-2 anemia in 5 patients, successfully managed with ESAs, and, thanks to the way of administration, also compliance is good. Peripheral neuropathy was seen in 48% (14/29) patients.
Conclusion
Bortezomib-lenalidomide-dexamethasone triplet, thanks to a notable proved synergistic mechanism of action between bortezomib and lenalidomide, had shown significant efficacy in severe setting of heavily pretreated patients, relapsed and refractory to bortezomib and lenalidomide.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Autologous bone marrow transplant, bortezomib, immunomodulation, Multiple Myeloma